A Phase 3, Open-label, Single-Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to &lt; 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

Ravulizumab in Pediatric Participants with TMA after HSCT

Comprehensive Cancer Center Mainfranken

Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)

Weitere solide Tumore

Phase III

Herr Prof. Dr. Matthias Wölfl

Herr Prof. Dr. Paul-Gerhardt Schlegel

Kinderklinik und Poliklinik

Universitätsklinikum Würzburg

Therapeutisch